» Articles » PMID: 15573866

Sigma Receptor Ligands: Applications in Inflammation and Oncology

Overview
Date 2004 Dec 3
PMID 15573866
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Sigma (sigma) receptors were initially proposed as a subtype of opiate receptors, and bind several psychoactive compounds. They are classified into sigma 1 (sigma1) and sigma 2 (sigma2) subtypes. The characterization of these subunits, and the discovery of new specific sigma receptor ligands, demonstrated that sigma receptors belong to a specific entity distinct from opiate receptors. Radioligand-binding data have recently demonstrated that the sigma1 subtype is related to a sterol isomerase, which is involved in the cholesterol biosynthesis pathway, and also to another protein of unknown function, SRBP2 (SR-31747 binding-protein 2), which shares a high homology with this enzyme. This complex group of proteins also binds molecules devoid of central effect, which demonstrate potent anti-inflammatory properties, and so are potentially useful in pathologies where pro-inflammatory cytokines are involved, particularly rheumatoid arthritis, Crohn's disease or psoriasis. In addition, the two sigma receptor subtypes and their two related proteins are also expressed on tumor cells, where they could be of prognostic relevance, and their ligands could potentially be used in the detection and targeting of tumors.

Citing Articles

The Benzoylpiperidine Fragment as a Privileged Structure in Medicinal Chemistry: A Comprehensive Review.

Bononi G, Lonzi C, Tuccinardi T, Minutolo F, Granchi C Molecules. 2024; 29(9).

PMID: 38731421 PMC: 11085656. DOI: 10.3390/molecules29091930.


Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes.

Oyer H, Sanders C, Kim F Front Pharmacol. 2019; 10:1141.

PMID: 31695608 PMC: 6816035. DOI: 10.3389/fphar.2019.01141.


Sigma Receptors as Endoplasmic Reticulum Stress "Gatekeepers" and their Modulators as Emerging New Weapons in the Fight Against Cancer.

Tesei A, Cortesi M, Zamagni A, Arienti C, Pignatta S, Zanoni M Front Pharmacol. 2018; 9:711.

PMID: 30042674 PMC: 6048940. DOI: 10.3389/fphar.2018.00711.


Effects of a selective sigma 1 antagonist compound on inflammatory pain.

Parenti C, Marrazzo A, Arico G, Cantarella G, Prezzavento O, Ronsisvalle S Inflammation. 2013; 37(1):261-6.

PMID: 24049016 DOI: 10.1007/s10753-013-9736-6.


A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.

Frecska E, Szabo A, Winkelman M, Luna L, McKenna D J Neural Transm (Vienna). 2013; 120(9):1295-303.

PMID: 23619992 DOI: 10.1007/s00702-013-1024-y.